drugset
Drugs / PROSTVAC (rilimogene galvacirepvec/rilimogene glafolivec) -V/TRICOM
last change Oct 2022 re-read 2 minutes ago

PROSTVAC (rilimogene galvacirepvec/rilimogene glafolivec) -V/TRICOM

also known as rilimogene glafolivec

Vaccine

Developed for
prostate cancer
Investigated by
National Cancer Institute (NCI)

Trials 1 · a red edge is where a trial was stopped

today NCT01867333 · Ph 2
20142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT01867333 Aug 2013 → Sep 2022 prostate cancer National Cancer Institute (NCI) Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as PROSTVAC (rilimogene galvacirepvec/rilimogene glafolivec) -V/TRICOM ClinicalTrials.gov intervention name — accepted as the source's own label NCT01867333 ↗
Known as rilimogene glafolivec “PROSTVAC (rilimogene galvacirepvec/rilimogene glafolivec) -V/TRICOM” NCT01867333 ↗
Modality Vaccine “A recombinant vaccinia virus vector vaccine containing the genes for human prostate-specific antigen (PSA) and three co-stimulatory molecules.” NCT01867333 ↗
Route Subcutaneous “vaccinia-PSA-TRICOM, 2x10(8) infectious units subcutaneously” NCT01867333 ↗